Do you plan to offer adjuvant olaparib to all gBRCA+ breast cancer whether TNBC or HR+?  

In subset analyses of OlympiA there seems to be smaller magnitude of benefit among HR+ patients. In your opinion, should adjuvant olabarib be offered to all patients regardless of HR status or reserved for higher risk TNBC population? 



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Colorado Permanente Medical Group Hematology & Oncology
If a patient with TNBC T1cNo and gBRCA1+ went to s...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution